<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>William Harvey Research Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C9EE698C-F86B-498B-B70B-D13D59747C6B"><gtr:id>C9EE698C-F86B-498B-B70B-D13D59747C6B</gtr:id><gtr:firstName>Yasunori</gtr:firstName><gtr:surname>Shintani</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1000461"><gtr:id>C2C09545-E599-4280-BBE8-6E5DD9545909</gtr:id><gtr:title>Novel TLR signalling that regulates the energy status of cardiomyocytes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000461</gtr:grantReference><gtr:abstractText>Heart diseases are one of the most common killers in both advanced and developing countries. There is a pressing need to develop new potential therapies, because there are few medicines useful in the final stages of heart failure. To prevent from or treat this disease, keeping the surviving heart cells healthy is very important. One option to achieve this is amplifying the naturally-occurring protective mechanisms that are activated in the body during stress. All organisms have such systems that protect themselves from injury such as infection or environmental stress. Recently it has been shown that certain molecules leaked from dead cells can sound an alarm in the situation of tissue injury. DNA from damaged cells is one of these. I have found that DNA administration reduced energy consumption of the heart, subsequently enhanced its tolerance to injury. Interestingly, this newly-found protective mechanism is brought about by a protein on the heart cells which was previously thought to produce a harmful effect to the heart cells by the immune system. This study aims to clarify the molecular mechanisms and further understand the nature of DNA-mediated heart protection by using established models and latest research technologies. Results obtained will lead to the development of novel therapeutic approaches for heart diseases. Also, it is plausible this self protection mechanism could be operative in other cell types, like brain cells, so likely opening new research areas. Altogether, this proposal certainly has a strong potential to impact on both basic and medical science.</gtr:abstractText><gtr:technicalSummary>An emerging concept in the fields of innate immunity is the danger model, in which Toll-like receptors (TLRs) on immune cells are activated by molecules released from injured self cells to induce inflammation. In fact, recent evidences have demonstrated the importance of TLRs in non-infectious insults such as ischaemia in various tissues. It is not surprising that TLRs are widely distributed in immune cells. However, their expression has also been reported in non-immune cells, like cardiomyocytes. TLR signalling induces inflammation which causes non-discriminational injury that is considered to be harmful to the heart, because most of cardiomyocytes are post-mitotic and have poor regenerative capacity. This gives the rise to a question, ?Do cardiomyocytes expressing TLRs sense pathogen/injured cells via TLRs and produce proinflammatory cytokines which damage themselves in an analogous way to immune cells?? The role of TLRs in cardiomyocytes still remains to be answered.
I have found that CpG oligodeoxynucleotide (a synthetic TLR9 ligand) reduced energy consumption of the heart in association with activation of AMP-activated protein kinase (AMPK), a ?master regulator? of cellular energy, which resulted in protection of cardiomyocytes from injury. Intriguingly, this self-protection programme occurred through a novel TLR9-mediated signalling pathway which is different from the canonical TLR signalling pathway in immune cells involving MyD88, NFeB and MAPK. 
This project is thus set to uncover the novel TLR9 signalling pathway in cardiomyocytes. The physiological role of this TLR9 signalling will be revealed by using cultured cardiomyocytes and Langendorff-perfused hearts of TLR9 knockout mice. The novel signalling molecular complex involving TLR9 will be identified by tandem affinity purification followed by proteomics approach using FLAG-HA tagged TLR9 in cardiomyocytes. Subsequently the molecular complex of TLR9 and spatiotemporal regulation of TLR9 between cardiomyocytes and immune cells will be assessed by biochemical and cell biological analyses to understand the regulation of the cell-type dependent signalling pathways. 
This project will have an impact on both basic and translational science. TLRs are originally thought to discriminate between self and non-self and to induce an inflammation by immune cells. However, in the meantime, the concept that the same ligand-receptor system can activate self-protection mechanisms in non-immune cells, will add new insights into our understanding of host defence system. In addition, once this novel TLR9 signalling is dissected, it could offer a new therapeutic target in treating heart diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>323091</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D666EC61-1D9A-4762-A54D-BA330D2B6B95"><gtr:id>D666EC61-1D9A-4762-A54D-BA330D2B6B95</gtr:id><gtr:title>Toll-like receptor 9 protects non-immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81d76b744822423451feedb714519aa7"><gtr:id>81d76b744822423451feedb714519aa7</gtr:id><gtr:otherNames>Shintani Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24933CD8-1FAA-42AA-8D5E-AB975ACEC5CF"><gtr:id>24933CD8-1FAA-42AA-8D5E-AB975ACEC5CF</gtr:id><gtr:title>The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b7c03fdffc5c99f5e9f015035b8a278"><gtr:id>3b7c03fdffc5c99f5e9f015035b8a278</gtr:id><gtr:otherNames>Narita T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A41EFAAC-1C98-46AC-9B9C-6F5F04A18BD0"><gtr:id>A41EFAAC-1C98-46AC-9B9C-6F5F04A18BD0</gtr:id><gtr:title>A simple and novel method for RNA-seq library preparation of single cell cDNA analysis by hyperactive Tn5 transposase.</gtr:title><gtr:parentPublicationTitle>Developmental dynamics : an official publication of the American Association of Anatomists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c28f1b0fa4a7ff43a579c838b92eae07"><gtr:id>c28f1b0fa4a7ff43a579c838b92eae07</gtr:id><gtr:otherNames>Brouilette S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-8388</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4E0894A-E1BD-40B4-AF6B-CA62A79E87EE"><gtr:id>D4E0894A-E1BD-40B4-AF6B-CA62A79E87EE</gtr:id><gtr:title>TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/81d76b744822423451feedb714519aa7"><gtr:id>81d76b744822423451feedb714519aa7</gtr:id><gtr:otherNames>Shintani Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B8C22F1-158F-4D11-AB6E-5BE7C2F856AE"><gtr:id>2B8C22F1-158F-4D11-AB6E-5BE7C2F856AE</gtr:id><gtr:title>Protective role of peroxisome proliferator-activated receptor-?/d in septic shock.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4f1999acfee26e30ace640022e21806d"><gtr:id>4f1999acfee26e30ace640022e21806d</gtr:id><gtr:otherNames>Kapoor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F04615FA-D65D-4530-9B43-C57C5781CA4C"><gtr:id>F04615FA-D65D-4530-9B43-C57C5781CA4C</gtr:id><gtr:title>Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc385318cc9406f2fb4b1c3b23a7852f"><gtr:id>bc385318cc9406f2fb4b1c3b23a7852f</gtr:id><gtr:otherNames>Lovell MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B5971137-A9CE-4300-B080-D1EC87D14F93"><gtr:id>B5971137-A9CE-4300-B080-D1EC87D14F93</gtr:id><gtr:title>The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b7c03fdffc5c99f5e9f015035b8a278"><gtr:id>3b7c03fdffc5c99f5e9f015035b8a278</gtr:id><gtr:otherNames>Narita T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C01ECF1-1994-4F19-B761-69A9B56D5B9D"><gtr:id>6C01ECF1-1994-4F19-B761-69A9B56D5B9D</gtr:id><gtr:title>Single-Cell Expression Profiling Reveals a Dynamic State of Cardiac Precursor Cells in the Early Mouse Embryo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ddaadbfdd7d61fd52e75561dd43de99"><gtr:id>9ddaadbfdd7d61fd52e75561dd43de99</gtr:id><gtr:otherNames>Kokkinopoulos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C994396B-45B7-4889-B2D5-CEA45C4622E5"><gtr:id>C994396B-45B7-4889-B2D5-CEA45C4622E5</gtr:id><gtr:title>Calcineurin splicing variant calcineurin A?1 improves cardiac function after myocardial infarction without inducing hypertrophy.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b52c027f944395e859c7fe9341d215d"><gtr:id>6b52c027f944395e859c7fe9341d215d</gtr:id><gtr:otherNames>Felkin LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49CA09AD-7292-4688-836B-5459C7C2AE55"><gtr:id>49CA09AD-7292-4688-836B-5459C7C2AE55</gtr:id><gtr:title>Evaluation of intramitochondrial ATP levels identifies G0/G1 switch gene 2 as a positive regulator of oxidative phosphorylation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a214f0fc7c5c61639a2e25373d50aaf"><gtr:id>1a214f0fc7c5c61639a2e25373d50aaf</gtr:id><gtr:otherNames>Kioka H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000461</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>